Cargando…
Peptide‐based therapeutic cancer vaccine: Current trends in clinical application
The peptide‐based therapeutic cancer vaccines have attracted enormous attention in recent years as one of the effective treatments of tumour immunotherapy. Most of peptide‐based vaccines are based on epitope peptides stimulating CD8(+) T cells or CD4(+) T helper cells to target tumour‐associated ant...
Autores principales: | Liu, Wensi, Tang, Haichao, Li, Luanfeng, Wang, Xiangyi, Yu, Zhaojin, Li, Jianping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088465/ https://www.ncbi.nlm.nih.gov/pubmed/33754407 http://dx.doi.org/10.1111/cpr.13025 |
Ejemplares similares
-
Silencing KIF18B enhances radiosensitivity: identification of a promising therapeutic target in sarcoma
por: Liu, Wensi, et al.
Publicado: (2020) -
Corrigendum to ‘Silencing KIF18B enhances radiosensitivity: Identification of a promising therapeutic target in sarcoma’ [EBioMedicine 61 (2020) 103,056]
por: Liu, Wensi, et al.
Publicado: (2021) -
Integrated microenvironment‐associated genomic profiles identify LRRC15 mediating recurrent glioblastoma‐associated macrophages infiltration
por: Tang, Haichao, et al.
Publicado: (2021) -
HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8(+) T and NK cells: a novel therapeutic tumour vaccine
por: Yu, Zhaojin, et al.
Publicado: (2021) -
Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine
por: Yu, Zhaojin, et al.
Publicado: (2021)